Core Viewpoint - Scienture Holdings, Inc. has terminated its Equity Line of Credit facility to focus on the commercial launch of its first FDA-approved product, Arbli, expected in Q3 2025 [1][3][4]. Financial Decisions - The cancellation of the ELOC was effective as of May 22, 2025, and a post-effective amendment was filed to deregister 310,488 unsold shares of common stock [2]. - The management believes that this strategic decision will allow for a focus on finding more favorable financing terms to support the company's growth strategy [4]. Product Launch - Arbli is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S., indicated for treating hypertension and related conditions in patients over 6 years old [3][4]. - The product is a peppermint-flavored suspension that does not require refrigeration and has a shelf life of 24 months at room temperature [5]. Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on providing novel specialty pharmaceutical products to meet unmet market needs [6]. - The company aims to enhance value for patients, physicians, and caregivers through its unique product offerings [6].
Scienture Holdings Announces Cancelation of ELOC